Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr:28:213-252.
doi: 10.1016/j.jtos.2023.04.004. Epub 2023 Apr 14.

TFOS Lifestyle: Impact of the digital environment on the ocular surface

Affiliations
Free article

TFOS Lifestyle: Impact of the digital environment on the ocular surface

James S Wolffsohn et al. Ocul Surf. 2023 Apr.
Free article

Abstract

Eye strain when performing tasks reliant on a digital environment can cause discomfort, affecting productivity and quality of life. Digital eye strain (the preferred terminology) was defined as "the development or exacerbation of recurrent ocular symptoms and/or signs related specifically to digital device screen viewing". Digital eye strain prevalence of up to 97% has been reported, due to no previously agreed definition/diagnostic criteria and limitations of current questionnaires which fail to differentiate such symptoms from those arising from non-digital tasks. Objective signs such as blink rate or critical flicker frequency changes are not 'diagnostic' of digital eye strain nor validated as sensitive. The mechanisms attributed to ocular surface disease exacerbation are mainly reduced blink rate and completeness, partial/uncorrected refractive error and/or underlying binocular vision anomalies, together with the cognitive demand of the task and differences in position, size, brightness and glare compared to an equivalent non-digital task. In general, interventions are not well established; patients experiencing digital eye strain should be provided with a full refractive correction for the appropriate working distances. Improving blinking, optimizing the work environment and encouraging regular breaks may help. Based on current, best evidence, blue-light blocking interventions do not appear to be an effective management strategy. More and larger clinical trials are needed to assess artificial tear effectiveness for relieving digital eye strain, particularly comparing different constituents; a systematic review within the report identified use of secretagogues and warm compress/humidity goggles/ambient humidifiers as promising strategies, along with nutritional supplementation (such as omega-3 fatty acid supplementation and berry extracts).

Keywords: Blinking; Blue-light; Computer vision syndrome; Digital display; Digital environment; Digital eye strain; Management; Nutrition; Systematic review; Visual fatigue.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest James S. Wolffsohn: 3m (F), AOS (C), Aston Vision Sciences (S), Atia Vision (C), Bausch & Lomb (C), Alcon (C,F), Allergan (F), CooperVision (C,F), CSIDryEye (C), DopaVision (C), Eyoto (S), Johnson & Johnson Vision (F), Rayner (F), M2C Pharmaceuticals (C,F), Medmont (C), Novartis (C,F), NuVision (C,F), Santen (C), Scope Ophthalmics (C,F), SightGlass (F, C), TFOS (S), Théa Laboratories (C,F), Topcon (F), The Eye Doctor (F), Veluon (F), Wolffsohn Research Limited (S), WO2019/001928 A1 (P), WO2019193051A1 (P). Gareth Lingham: None (N). Laura E. Downie: Alcon (F), Azura Ophthalmics (F), BCLA (R), CooperVision (F), Cornea and Contact Lens Society of Australia (R), Medmont International (R), NHMRC Australia (F), Novartis (F), TFOS (S), dry eye diagnostic method (P). Byki Huntjens: Alcon (C), Bausch and Lomb (C), CooperVision (C), Johnson & Johnson Vision Care Institute (C). Takenori Inomata: Novartis (F), Santen (F,C), Lion Corporation (F), SEED Company (F), Johnson & Johnson (F), Hogy Medical Co (F), Shin Nippon Biomedical Laboratories (F), Renatech (P), Kowa (P), InnoJin (E). Saleel Jivraj: IMED Pharma (F, C), The Body Doctor (F), DryiRelief App (I), My Myopia Management App (I), Optometrist Calgary (P), Alcon (C). Emmanuel Kobia-Acquah: None (N) Alex Muntz: Azura Ophthalmics (F), . Karim Mohamed-Noriega:None (N) Sotiris Plainis: None (N). Michael Read: Johnson & Johnson Vision (F), Coopervision (C), Menicon (F), Visco Vision inc (F), US10959973B2 (P). Rony R. Sayegh: Novartis (C), Allergan (C), US20220175516A1 (P). Sumeer Singh: None (N). Tor P. Utheim: ABIGO (F), Alcon (F,C), Allergan (F), AMWO (F), Bausch&Lomb (F), Bayer (F,C), European school for advanced studies in ophthalmology (F,C), InnZ Medical (F), Medilens Nordic (F), Medistim (F), Novartis (F,C), Santen (F,C), Specsavers (F,C), Shire Pharmaceuticals (F,C), Thea Laboratoires (F,C). Jennifer P. Craig: Adelphi Values Ltd (R), Alcon (F,R,C), Asta Supreme (R), Azura Ophthalmics (F,R), E-Swin (F,R), Johnson & Johnson Vision (R), Manuka Health (F), Medmont International (R), Novoxel (R), Oculeve (F), Photon Therapeutics (R), Resono Ophthalmic (F,R), TFOS (S), Théa Laboratories (F,R), Topcon (F,R), TRG Natural Pharmaceuticals (F,R).

Comment in

Publication types